Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
Conclusions/interpretationIn people with diabetes, GLP1RA use was associated with significantly reduced risks of MALE compared with SGLT2i within the first 2 years after initiation, especially among people with diabetic neuropathy.Graphical abstract
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Angioplasty | Brain | Cardiology | Cardiovascular | Databases & Libraries | Diabetes | Diabetes Mellitus | Endocrinology | Health Insurance | Heart | Heart Attack | Heart Failure | Insurance | Ischemic Stroke | Neurology | Peripheral Angioplasty | Peripheral Neuropathy | Peripheral Vascular Disease (PVD) | SGLT2 Inhibitors | Sodium | Stroke | Study | Taiwan Health